Patients’ characteristics (n = 107).
| Values | |
|---|---|
| Age, yrs | 49.7 (12.5) |
| Sex, M:F | 53:54 |
| Tender joint count | 5.5 (8.5) |
| Swollen joint count | 1.1 (2.8) |
| CRP, mg/L | 6 (7) |
| DAPSA | 15.3 (12.1) |
| LEI | 1 (1.2) |
| MASES | 1.4 (2.5) |
| Dactylitis, n (%) | 16 (15) |
| PASI | 3.8 (8.5) |
| Low back prevalence, n (%) | 68 (63.5) |
| IBP prevalence, n (%) | 31 (29) |
| Back pain intensity (patient VAS 0–10) | 3.3 (3.3) |
| BASDAI | 3.9 (2.4) |
| ASDAS-CRP | 0.9 (2.2) |
| BASMI | 2.7 (1.2) |
| BASFI | 2.9 (2.3) |
| Current medication use, n (%) | |
| sDMARD | 51 (47.7) |
| Apremilast | 1 (0.9) |
| Biologics | 41 (38.3) |
| Anti-TNF | 35 (32.7) |
| Anti-IL-17 | 1 (0.9) |
| Anti-IL-12/23 | 3 (2.8) |
| MRI SIJ scores | |
| Total Berlin score | 6.9 (10.7) |
| Osteitis/BME (0–24) | 1.6 (3.3) |
| Fat infiltration score (0–24) | 1.3 (3.5) |
| Erosion score (0–24) | 3.4 (5.8) |
| Sclerosis score (0–8) | 0.4 (1.2) |
| Ankylosis score (0–8) | 0.3 (1.4) |
Values are expressed as mean (SD) unless otherwise stated. ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; BME: bone marrow edema; CRP: C-reactive protein; DAPSA: Disease Activity Index for Psoriatic Arthritis; IBP: inflammatory back pain; IL: interleukin; LEI: Leeds Enthesitis Index; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; MRI: magnetic resonance imaging; PASI: Psoriasis Area and Severity Index; sDMARD; synthetic disease-modifying antirheumatic drug; SIJ: sacroiliac joint; TNF: tumor necrosis factor; VAS: visual analog scale.